Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer

To evaluate the safety and efficacy of the combination of cisplatin on day 1 and docetaxel on days 1, 8 and 15 every 4 weeks for the treatment of previously untreated patients with non-small-cell lung cancer (NSCLC). A group of 38 patients with advanced or metastatic NSCLC who had not received prior...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2004-08, Vol.54 (2), p.173-177
Main Authors: TSUNODA, Toshiyuki, KOIZUMI, Tomonobu, HAYASAKA, Muneharu, HIRAI, Kazuya, KOYAMA, Shigeru, TAKABAYASHI, Yasuki, FUJIMOTO, Keisaku, KUBO, Keishi
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Cisplatin - administration & dosage
Cisplatin - adverse effects
Drug Administration Schedule
Female
Humans
Infusions, Intravenous
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Male
Medical sciences
Middle Aged
Neutropenia - chemically induced
Pharmacology. Drug treatments
Survival Analysis
Taxoids - administration & dosage
Taxoids - adverse effects
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the safety and efficacy of the combination of cisplatin on day 1 and docetaxel on days 1, 8 and 15 every 4 weeks for the treatment of previously untreated patients with non-small-cell lung cancer (NSCLC). A group of 38 patients with advanced or metastatic NSCLC who had not received prior treatment and who were aged under 75 years were enrolled. The patients received intravenous infusions of docetaxel (25 mg/m2, days 1, 8, 15) and cisplatin (80 mg/m2, day 1), followed by a week of rest. Six patients had grade 3/4 neutropenia (18%), but there were no episodes of neutropenic fever. Nonhematologic toxicities were also mild. There were 12 partial responses for an objective response rate of 31.6%. The median survival was 11.8 months, and the 1-year survival rate was 46.5%. Cisplatin combined with weekly administration of docetaxel is efficacious against NSCLC with low hematotoxicity, and this schedule may be an alternative for the treatment of NSCLC.
ISSN:0344-5704
1432-0843
DOI:10.1007/s00280-004-0810-5